The combination of metformin and L-asparaginase offers a promising therapeutic strategy by simultaneously disrupting mitochondrial oxidative phosphorylation, amino acid metabolism, and glycolysis, thereby exploiting the metabolic heterogeneity and adaptability of DLBCL. The gene discussed is ASPG; the disease is diffuse large B-cell lymphoma.